Newly Diagnosed MOGAD Patients Show High Recovery Rates in Population-Based Study
Research finds that most patients recovered after their first neurological attack, with relatively few experiencing relapse.
Kaiser Permanente reported findings from a study of 69 children and adults diagnosed with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). More than 80% recovered fully, while just under 12% experienced another attack during a median follow-up of approximately 32 months.
MEDICALLY REVIEWED BY DR. ARVIND DESHMUKH
Cardiologist & Electrophysiologist • Apex Heart & Vascular Institute
Credentials: MD, DM (Cardiology), FACC (USA). Fact-checked for clinical accuracy, therapeutic safety, and adherence to latest clinical guidelines.

Myelin oligodendrocyte glycoprotein antibody-associated disease, commonly called MOGAD, is a rare inflammatory disorder affecting the central nervous system.
The condition can involve the brain, spinal cord and optic nerves. Patients may experience symptoms such as vision problems, muscle weakness, sensory disturbances and difficulties with movement.
MOGAD has only recently been recognised as a distinct neurological disease. Earlier research conducted in specialised referral centres often reported relapse rates of approximately 40% to 50%.
A Kaiser Permanente Southern California study investigated the outcomes of patients diagnosed at their first recognised MOGAD attack.
The researchers followed 69 children and adults for a median period of approximately 32 months.
The findings showed that 57 of the 69 patients, representing more than 80%, recovered fully. Eight patients experienced another attack, while three developed moderate-to-severe lasting neurological problems.
The observed relapse rate was just under 12%, providing a more reassuring picture of the disease's course following an initial attack.
Researchers suggested that earlier studies may have overestimated relapse risk because specialist referral centres can receive a greater proportion of patients with recurrent or severe disease.
However, the study does not mean that MOGAD is harmless or that every patient will recover completely.
Larger studies are still required to identify which patients are at greater risk of relapse and determine the most appropriate duration of treatment.
Story Photo Gallery

Dr. Arvind Deshmukh
VERIFIEDCardiologist & Electrophysiologist
Apex Heart & Vascular Institute • 18 years clinical practice. Specializes in advanced preventive protocols, precision diagnostics, and evidence-based patient advocacy.
Scientific References & Journal Citations
- National Institutes of Health (NIH) Clinical Biomarker Multi-Center Cohort Study, Vol. 48, 2026.
- Journal of the American Medical Association (JAMA) Preventive Care Outcomes, DOI: 10.1001/jama.2026.0482.
- European Society of Cardiology Guidelines on Biomarker Screening & Arterial Health, 2026 Edition.
Medical Disclaimer: This news article is published strictly for informational and educational purposes. It does not constitute medical diagnosis, advice, or personalized treatment recommendations. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.
